- Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromabScribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its Nasdaq listing at $14 per share, the midpoint of the ...Endpoints · 7d ago↗ source
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…BioSpace · 7d ago↗ source
- J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B dealJohnson & Johnson and AbbVie, the two pharma giants already in the psychedelic space, also eyed AtaiBeckley, according to a source familiar with the situation, but didn’t make an offer before E…